My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Stellant Securities (India) reports standalone net loss of Rs 0.07 crore in the March 2017 quarter
May 31,2017

Net Loss of Stellant Securities (India) reported to Rs 0.07 crore in the quarter ended March 2017 as against net loss of Rs 0.07 crore during the previous quarter ended March 2016. Sales reported to Rs 4.20 crore in the quarter ended March 2017. There were no Sales reported during the previous quarter ended March 2016.

For the full year,net profit reported to Rs 0.02 crore in the year ended March 2017 as against net loss of Rs 0.03 crore during the previous year ended March 2016. Sales rose 2788.24% to Rs 4.91 crore in the year ended March 2017 as against Rs 0.17 crore during the previous year ended March 2016.

ParticularsQuarter EndedYear Endedn++Mar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var. Sales4.200 0 4.910.17 2788 OPM %-1.670 -0.41-17.65 - PBDT-0.07-0.07 0 0.02-0.03 LP PBT-0.07-0.07 0 0.02-0.03 LP NP-0.07-0.07 0 0.02-0.03 LP

Powered by Capital Market - Live News

State Trading Corporation of India standalone net profit declines 52.28% in the March 2017 quarter
May 31,2017

Net profit of State Trading Corporation of India declined 52.28% to Rs 7.95 crore in the quarter ended March 2017 as against Rs 16.66 crore during the previous quarter ended March 2016. Sales rose 400.88% to Rs 2797.59 crore in the quarter ended March 2017 as against Rs 558.54 crore during the previous quarter ended March 2016.

For the full year,net loss reported to Rs 165.54 crore in the year ended March 2017 as against net profit of Rs 17.86 crore during the previous year ended March 2016. Sales declined 26.02% to Rs 7752.16 crore in the year ended March 2017 as against Rs 10479.16 crore during the previous year ended March 2016.

ParticularsQuarter EndedYear Endedn++Mar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var. Sales2797.59558.54 401 7752.1610479.16 -26 OPM %1.237.58 -1.711.31 - PBDT6.8413.72 -50 11.1314.80 -25 PBT2.918.65 -66 -4.64-1.08 -330 NP7.9516.66 -52 -165.5417.86 PL

Powered by Capital Market - Live News

Switching Technologies Gunther reports standalone net loss of Rs 0.09 crore in the March 2017 quarter
May 31,2017

Net Loss of Switching Technologies Gunther reported to Rs 0.09 crore in the quarter ended March 2017 as against net loss of Rs 0.46 crore during the previous quarter ended March 2016. Sales declined 2.33% to Rs 3.36 crore in the quarter ended March 2017 as against Rs 3.44 crore during the previous quarter ended March 2016.

For the full year,net loss reported to Rs 0.50 crore in the year ended March 2017 as against net loss of Rs 0.96 crore during the previous year ended March 2016. Sales rose 5.56% to Rs 15.58 crore in the year ended March 2017 as against Rs 14.76 crore during the previous year ended March 2016.

ParticularsQuarter EndedYear Endedn++Mar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var. Sales3.363.44 -2 15.5814.76 6 OPM %-2.08-12.79 --2.44-5.56 - PBDT-0.05-0.42 88 -0.35-0.80 56 PBT-0.09-0.46 80 -0.50-0.96 48 NP-0.09-0.46 80 -0.50-0.96 48

Powered by Capital Market - Live News

Aegis Logistics consolidated net profit declines 5.61% in the March 2017 quarter
May 31,2017

Net profit of Aegis Logistics declined 5.61% to Rs 29.77 crore in the quarter ended March 2017 as against Rs 31.54 crore during the previous quarter ended March 2016. Sales rose 190.13% to Rs 1267.78 crore in the quarter ended March 2017 as against Rs 436.97 crore during the previous quarter ended March 2016.

For the full year,net profit rose 6.11% to Rs 120.26 crore in the year ended March 2017 as against Rs 113.33 crore during the previous year ended March 2016. Sales rose 77.70% to Rs 3932.81 crore in the year ended March 2017 as against Rs 2213.22 crore during the previous year ended March 2016.

ParticularsQuarter EndedYear Endedn++Mar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var. Sales1267.78436.97 190 3932.812213.22 78 OPM %4.1011.50 -5.268.37 - PBDT49.2748.46 2 196.00176.09 11 PBT43.3242.43 2 171.70152.67 12 NP29.7731.54 -6 120.26113.33 6

Powered by Capital Market - Live News

PDS Multinational Fashions reports consolidated net loss of Rs 6.44 crore in the March 2017 quarter
May 31,2017

Net loss of PDS Multinational Fashions reported to Rs 6.44 crore in the quarter ended March 2017 as against net profit of Rs 14.61 crore during the previous quarter ended March 2016. Sales rose 11.93% to Rs 1347.30 crore in the quarter ended March 2017 as against Rs 1203.65 crore during the previous quarter ended March 2016.

ParticularsQuarter Endedn++Mar. 2017Mar. 2016% Var. Sales1347.301203.65 12 OPM %1.412.19 - PBDT15.9922.76 -30 PBT12.7318.50 -31 NP-6.4414.61 PL

Powered by Capital Market - Live News

Man Infraconstruction consolidated net profit rises 490.06% in the March 2017 quarter
May 31,2017

Net profit of Man Infraconstruction rose 490.06% to Rs 19.00 crore in the quarter ended March 2017 as against Rs 3.22 crore during the previous quarter ended March 2016. Sales rose 161.38% to Rs 163.60 crore in the quarter ended March 2017 as against Rs 62.59 crore during the previous quarter ended March 2016.

For the full year,net profit rose 201.36% to Rs 53.01 crore in the year ended March 2017 as against Rs 17.59 crore during the previous year ended March 2016. Sales rose 99.49% to Rs 451.71 crore in the year ended March 2017 as against Rs 226.43 crore during the previous year ended March 2016.

ParticularsQuarter EndedYear Endedn++Mar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var. Sales163.6062.59 161 451.71226.43 99 OPM %31.9523.12 -23.4415.45 - PBDT48.6113.15 270 114.7050.57 127 PBT46.1011.10 315 107.0042.66 151 NP19.003.22 490 53.0117.59 201

Powered by Capital Market - Live News

Ganesh Benzoplast standalone net profit declines 92.57% in the March 2017 quarter
May 31,2017

Net profit of Ganesh Benzoplast declined 92.57% to Rs 3.18 crore in the quarter ended March 2017 as against Rs 42.79 crore during the previous quarter ended March 2016. Sales rose 4.21% to Rs 31.21 crore in the quarter ended March 2017 as against Rs 29.95 crore during the previous quarter ended March 2016.

For the full year,net profit declined 73.53% to Rs 12.75 crore in the year ended March 2017 as against Rs 48.16 crore during the previous year ended March 2016. Sales declined 1.10% to Rs 118.12 crore in the year ended March 2017 as against Rs 119.43 crore during the previous year ended March 2016.

ParticularsQuarter EndedYear Endedn++Mar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var. Sales31.2129.95 4 118.12119.43 -1 OPM %18.4233.12 -31.9031.33 - PBDT5.757.09 -19 25.9022.97 13 PBT3.426.57 -48 14.8812.25 21 NP3.1842.79 -93 12.7548.16 -74

Powered by Capital Market - Live News

TTK Healthcare standalone net profit declines 6.06% in the March 2017 quarter
May 31,2017

Net profit of TTK Healthcare declined 6.06% to Rs 5.58 crore in the quarter ended March 2017 as against Rs 5.94 crore during the previous quarter ended March 2016. Sales declined 0.07% to Rs 119.54 crore in the quarter ended March 2017 as against Rs 119.62 crore during the previous quarter ended March 2016.

For the full year,net profit declined 14.73% to Rs 19.33 crore in the year ended March 2017 as against Rs 22.67 crore during the previous year ended March 2016. Sales rose 2.99% to Rs 530.43 crore in the year ended March 2017 as against Rs 515.03 crore during the previous year ended March 2016.

ParticularsQuarter EndedYear Endedn++Mar. 2017Mar. 2016% Var.Mar. 2017Mar. 2016% Var. Sales119.54119.62 0 530.43515.03 3 OPM %8.288.87 -7.417.86 - PBDT11.0311.08 0 41.9342.74 -2 PBT8.108.43 -4 30.0635.53 -15 NP5.585.94 -6 19.3322.67 -15

Powered by Capital Market - Live News

Asian Star Company announces demise of director
May 31,2017

Asian Star Company announced the sad demise of Hasmukh B. Gandhi, Independent Director of the Company on 24 May 2017.

Powered by Capital Market - Live News

Glenmark Pharma gets healthier after getting USFDA nod for generic drug
May 31,2017

The announcement was made during market hours today, 31 May 2017.

Meanwhile, the BSE Sensex was up 21.09 points, or 0.07%, to 31,180.49.

On the BSE, 1.13 lakh shares were traded in the counter so far, compared with average daily volumes of 1.18 lakh shares in the past one quarter. The stock had hit a high of Rs 643.15 and a low of Rs 630 so far during the day. The stock had hit a 52-week high of Rs 993 on 1 November 2016. The stock had hit a 52-week low of Rs 600 on 29 May 2017.

The stock had underperformed the market over the past one month till 30 May 2017, sliding 30.04% compared with 4.15% gains in the Sensex. The scrip had underperformed the market in past one quarter, declining 32.52% as against Sensexs 8.41% gains. The scrip had also underperformed the market in past one year, dropping 28.73% as against Sensexs 16.59% gains.

The large-cap company has equity capital of Rs 28.22 crore. Face value per share is Re 1.

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Atomoxetine Capsules USP, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg, the generic version of Strattera Capsules, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg, of Eli Lilly and Company.

According to IMS Health sales data for the 12 month period ended April 2017, the Strattera Capsules, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg market achieved annual sales of approximately $1.1 billion in US.

Glenmarks current portfolio consists of 117 products authorized for distribution in the US marketplace and approximately 67 abbreviated new drug application (ANDA)s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Meanwhile, Glenmark Pharmaceuticals had announced on 29 May 2017 that it was granted final approval by the United States Food & Drug Administration for Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg, the generic version of Bystolic Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg, of Forest Laboratories, LLC (Forest).

On a consolidated basis, Glenmark Pharmaceuticals net profit rose 23.5% to Rs 183.76 crore on 10.2% rise in net sales to Rs 2424.41 crore in Q4 March 2017 over Q4 March 2016.

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical organization headquartered at Mumbai, India. The company is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).

Powered by Capital Market - Live News

Sharda Motors hits the roof after strong Q4 result
May 31,2017

The result was announced after market hours yesterday, 30 May 2017.

Meanwhile, the S&P BSE Sensex was up 60.44 points, or 0.19%, to 31,219.84. The S&P BSE Mid-Cap index was up 172.41 points, or 1.16%, to 15,096.45.

On BSE, so far 6,990 shares were traded in the counter, compared with an average volume of 1,891 shares in the past one quarter. The stock hit a high of Rs 2,144.90 and a low of Rs 1,925 so far during the day. The stock hit a record high of Rs 2,170 on 21 April 2017. The stock hit a 52-week low of Rs 795 on 30 May 2016.

The stock had underperformed the market over the past one month till 30 May 2017, sliding 6.68% compared with 4.15% gains in the Sensex. The scrip had, however, outperformed the market in past one quarter, rising 23.92% as against Sensexs 8.41% gains. The scrip had also outperformed the market in past one year, advancing 115.88% as against Sensexs 16.59% gains.

The small-cap company has an equity capital of Rs 5.95 crore. Face value per share is Rs 10.

Sharda Motor Industries board of directors has recommended a final dividend of Rs 6.25 per share for the year ended 31 March 2017.

Sharda Motor Industries operates in the automotive industry. The company is one of the leading manufacturers of exhaust systems, suspension systems, seat trim and seat frames.

Powered by Capital Market - Live News

Jaiprakash Associates signs definitive agreement with Orient Cement
May 31,2017

Jaiprakash Associates has executed today a definitive agreement with Orient Cement (OCL), a part of CK Birla Group, as authorized by the Board of Directors of the Company on 6 October 2016 for acquisition by OCL of Companys 74% equity stake in Bhilai Jaypee Cement (BJCL) based on an Enterprise Value of Rs. 1,450 crore on a cash free and debt free basis and subject to adjustments on account of Working Capital, if any and subject to approval of SAIL, approval of lenders of BJCL besides other statutory & regulatory approvals, as applicable.

Powered by Capital Market - Live News

Jaiprakash Power Ventures executes sale agreement with Orient Cement
May 31,2017

Jaiprakash Power Ventures has executed an agreement with Orient Cement for sale of 2 million ton per annum Nigrie Cement Grinding Unit on a going concern basis at a consideration linked to a total enterprise value of approximately Rs 496 crore subject to mutually agreed adjustments and all such approvals, as might be required.

Powered by Capital Market - Live News

Orient Cement to acquire two cement entities
May 31,2017

Orient Cement announced that the Company has signed the definitive agreements:

(1) for the acquisition by the Company of 28,09,66,752 equity shares of Bhilai Jaypee Cement (BJCL) from Jaiprakash Associates (JAL) and its nominee for a for a total enterprise value of Rs. 1450 crore.

(2)for the acquisition by the Company of the Nigrie Cement Grinding Unit (Business Undertaking) as going concern from Jaiprakash Power Ventures (JPVL) for a total consideration of Rs. 496 crore.

Powered by Capital Market - Live News

Orient Cement signs definitive agreements
May 31,2017

Orient Cement announced that the Company has signed the definitive agreements:

(1) for the acquisition by the Company of 28,09,66,752 equity shares of Bhilai Jaypee Cement (BJCL) from Jaiprakash Associates (JAL) and its nominee for a for a total enterprise value of Rs. 1450 crore.

(2)for the acquisition by the Company of the Nigrie Cement Grinding Unit (Business Undertaking) as going concern from Jaiprakash Power Ventures (JPVL) for a total consideration of Rs. 496 crore.

Powered by Capital Market - Live News